Although adipose tissue and cells show considerable promise for clinical translation in the emerging field of regenerative medicine, they present a challenge to the regulatory community both nationally and internationally. This commentary evaluates the status of adipose-derived therapeutics and considers regulatory approaches designed to maximize patient safety while advancing clinical translation in accordance with evidence-based medical science.
|Number of pages||6|
|Journal||Stem Cells and Development|
|State||Published - 1 Mar 2020|
- adipose-derived stromal/stem cells
- cell therapy
- regenerative medicine
- stromal vascular fraction cells